Top

Published in:

Open Access 01-12-2023 | Human Papillomavirus | Research

Impact of CD40 gene polymorphisms on the risk of cervical squamous cell carcinoma: a case-control study

Authors: Manning Zhu, Xiaoying Li, Yanan Feng, Tianshuang Jia, Songxue Li, Liping Gong, Shuang Dong, Xianchao Kong, Litao Sun

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

Cervical cancer is the fourth most common cancer among women worldwide. Genome-wide association studies have revealed multiple susceptible genes and their polymorphisms for cervical cancer risk. Therefore, we aimed to investigate the correlation between single nucleotide polymorphisms (SNPs) of the CD40 gene and susceptibility to cervical squamous cell carcinoma (CSCC) in a population from the northeastern Han Chinese population.

Methods

The three SNPs (rs1800686, rs3765459, and rs4810485) of the CD40 gene were analyzed by multiplex polymerase chain reaction (PCR) combined with next-generation sequencing methods in 421 patients with CSCC, 594 patients with high-grade squamous intraepithelial lesions (HSIL), and 504 healthy females. Multivariate logistic regression analysis was used to analyze the potential relationship between CD40 gene polymorphisms and CSCC, or HSIL.

Results

Our research results showed the AA genotype of rs1800686 had a protective effect on CSCC in comparison to the GG genotype and AG+GG genotypes (AA vs. GG: p = 0.0389 and AA vs. AG+GG: p = 0.0280, respectively). After FDR correction, the results were still statistically significant (p = 0.0389 and p = 0.0389, respectively). Similarly, rs3765459 showed a reduced risk association for CSCC in the codominant and recessive models (AA vs. GG: p = 0.0286 and AA vs. AG+GG: p = 0.0222, respectively). Significant differences remained after FDR correction (p = 0.0286 and p = 0.0286, respectively). However, these differences were no longer significant after the Bonferroni correction. In addition, the genotypes for the rs4810485 polymorphisms were associated with parity of the patients with CSCC. The genotypes for the rs3765459 polymorphisms were significantly correlated with the D-dimer of the patients with CSCC. The 3 SNPs genotypes of the CD40 gene were closely related to the squamous cell carcinoma antigen (SCC) of the patients with HSIL.

Conclusions

The CD40 gene may play a role in the occurrence and development of CSCC.

Available only for authorised users

Das M. WHO launches strategy to accelerate elimination of cervical cancer[J]. Lancet Oncol. 2021;22(1):20–1. https://doi.org/10.1016/S1470-2045(20)30729-4.CrossRefPubMed

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 Countries[J]. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl). 2021;134(7):783–91. https://doi.org/10.1097/CM9.0000000000001474.CrossRefPubMed

Danolic D, Heffer M, Wagner J, et al. Role of ganglioside biosynthesis genetic polymorphism in cervical cancer development[J]. J Obstet Gynaecol. 2020;40(8):1127–32. https://doi.org/10.1080/01443615.2019.1692801.CrossRefPubMed

Ginsburg O, Horton R. A Lancet Commission on women and cancer[J]. Lancet. 2020;396(10243):11–3. https://doi.org/10.1016/S0140-6736(20)31479-3.CrossRefPubMed

Li J, Gao JJ, Li N, et al. Distribution of human papillomavirus genotypes in western China and their association with cervical cancer and precancerous lesions[J]. Arch Virol. 2021;166(3):853–62. https://doi.org/10.1007/s00705-021-04960-z.CrossRefPubMed

Xu H, Zhang J. [Interpretation of updated pathological contents for cervical cancer in NCCN clinical practice guidelines, version 1, 2020][J]. Zhonghua Bing Li Xue Za Zhi. 2021;50(1):9–13. https://doi.org/10.3760/cma.j.cn112151-20200712-00548.CrossRefPubMed

Nahand JS, Taghizadeh-Boroujeni S, Karimzadeh M, Borran S, Pourhanifeh MH, Moghoofei M, et al. microRNAs: New prognostic, diagnostic, and therapeutic biomarkers in cervical cancer. J Cell Physiol. 2019;234:17064–99.CrossRefPubMed

Magnusson PK, Lichtenstein P, Gyllensten UB. Heritability of cervical tumours. Int J Cancer. 2000;88:698–701.CrossRefPubMed

10.

Bahrami A, Hasanzadeh M, Shahidsales S, et al. Genetic susceptibility in cervical cancer: from bench to bedside[J]. J Cell Physiol. 2018;233(3):1929–39. https://doi.org/10.1002/jcp.26019.CrossRefPubMed

11.

Jendoubi-Ferchichi M, Satouri L, Ghoul F, Malek-Mellouli M, Derbel AM, Makni MK, et al. Phylogeny and classification of human papillomavirus (HPV)16 and HPV18 variants based on E6 and L1 genes in tunisian women with cervical lesions. Asian Pac J Cancer Prev. 2018;19(12):3361–6. https://doi.org/10.31557/APJCP.2018.19.12.3361.CrossRefPubMedPubMedCentral

12.

Graham SV. Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies. Future Microbiol. 2010;5(10):1493–506. https://doi.org/10.2217/fmb.10.107.CrossRefPubMed

13.

Horvath CA, Boulet GA, Renoux VM, Delvenne PO, Bogers JP. Mechanisms of cell entry by human papillomaviruses: an overview. Virol J. 2010;7:11. https://doi.org/10.1186/1743-422X-7-11.CrossRefPubMedPubMedCentral

14.

Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17. https://doi.org/10.1128/CMR.16.1.1-17.2003.CrossRefPubMedPubMedCentral

15.

Bletsa G, Zagouri F, Amoutzias GD, Nikolaidis M, Zografos E, Markoulatos P, et al. Genetic variability of the HPV16 early genes and LCR. Present and future perspectives. Expert Rev Mol Med. 2021;23:e19. https://doi.org/10.1017/erm.2021.18.CrossRefPubMed

16.

Ault KA. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol Oncol. 2007;107(2 Suppl 1). https://doi.org/10.1016/j.ygyno.2007.08.059. S31-3.

17.

Wang LN, Wang L, Cheng G, Dai M, Yu Y, Teng G, et al. The association of telomere maintenance and TERT expression with susceptibility to human papillomavirus infection in cervical epithelium. Cell Mol Life Sci. 2022;79(2):110. https://doi.org/10.1007/s00018-021-04113-0.CrossRefPubMed

18.

Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889–99. https://doi.org/10.1016/S0140-6736(13)60022-7.CrossRefPubMed

19.

Takeuchi F, Kukimoto I, Li Z, Li S, Li N, Hu Z, et al. Genome-wide association study of cervical cancer suggests a role for ARRDC3 gene in human papillomavirus infection. Hum Mol Genet. 2019;28(2):341–8. https://doi.org/10.1093/hmg/ddy390.CrossRefPubMed

20.

Chen D, Cui T, Ek WE, Liu H, Wang H, Gyllensten U. Analysis of the genetic architecture of susceptibility to cervical cancer indicates that common SNPs explain a large proportion of the heritability. Carcinogenesis. 2015;36(9):992–8. https://doi.org/10.1093/carcin/bgv083.CrossRefPubMed

21.

Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis. J Pathol. 2007;212(4):356–67. https://doi.org/10.1002/path.2192.CrossRefPubMed

22.

Morio T, Hanissian S, Geha RS. Characterization of a 23-kDa protein associated with CD40[J]. Proc Natl Acad Sci U S A. 1995;92(25):11633–6. https://doi.org/10.1073/pnas.92.25.11633.CrossRefPubMedPubMedCentral

23.

Quezada SA, Jarvinen LZ, Lind EF, et al. CD40/CD154 interactions at the interface of tolerance and immunity[J]. Annu Rev Immunol. 2004;22:307–28. https://doi.org/10.1146/annurev.immunol.22.012703.104533.CrossRefPubMed

24.

AbdelGhafar MT, El-Kholy RA, Elbedewy TA, et al. Impact of CD40 gene polymorphisms on the risk of immune thrombocytopenic purpura[J]. Gene. 2020;736:144419. https://doi.org/10.1016/j.gene.2020.144419.CrossRefPubMed

25.

Zhang Y, Wang N, Ding M, et al. CD40 accelerates the Antigen-Specific Stem-Like Memory CD8(+) T cells formation and human papilloma virus (HPV)-Positive tumor Eradication[J]. Front Immunol. 2020;11:1012. https://doi.org/10.3389/fimmu.2020.01012.CrossRefPubMedPubMedCentral

26.

Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 2007;13:1083–8. https://doi.org/10.1158/1078-0432.CCR-06-1893.CrossRefPubMed

27.

Huang Q, Qu QX, Xie F, et al. CD40 is overexpressed by HPV16/18-E6 positive cervical carcinoma and correlated with clinical parameters and vascular density[J]. Cancer Epidemiol. 2011;35(4):388–92. https://doi.org/10.1016/j.canep.2010.12.004.CrossRefPubMed

28.

Seran CH, Sarah JY, Stephen M, Glyn RT, Amanda JB, Andrew H, et al. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol (Baltimore Md : 1950). 2005;174(1):41–50. https://doi.org/10.4049/jimmunol.174.1.41.CrossRef

29.

Huang Q, Qu QX, Xie F, Hu JM, Chen YG, Zhang XG. Sensitization of SiHa cell to gemcitabine by CD40 activation and its overexpression in cervical carcinoma. Med Oncol. 2011;28:781–8.CrossRefPubMed

30.

Altenburg A, Abdel-Naser MB, Nikolakis G, et al. CD40/CD40 ligand interactions and TNFα treatment reduce activity of P105 promoter of the human papilloma virus-18 in vitro[J]. Exp Oncol. 2016;38(1):22–5.CrossRefPubMed

31.

Nieters A, Bracci PM, de Sanjosé S, et al. A functional TNFRSF5 polymorphism and risk of non-hodgkin lymphoma, a pooled analysis[J]. Int J Cancer. 2011;128(6):1481–5. https://doi.org/10.1002/ijc.25420.CrossRefPubMed

32.

Shuang C, Dalin L, Weiguang Y, Zhenkun F, Fengyan X, Da P, et al. Association of CD40 gene polymorphisms with sporadic breast cancer in chinese Han women of Northeast China. PLoS ONE. 2011;6:e23762. https://doi.org/10.1371/journal.pone.0023762.CrossRefPubMedPubMedCentral

33.

Zhou G, Wang Y, Fang Z, et al. CD40 -1 C > T polymorphism and the risk of lung cancer in a chinese population[J]. Int J Clin Exp Pathol. 2015;8(11):15163–9.PubMedPubMedCentral

34.

Tang W, Xue L, Yan Q, Cai S, Bai Y, Lin L, et al. Association of single nucleotide polymorphisms in the apoptosis-related genes TP63 and CD40 with risk for Lung Cancer in a chinese Han Population. Tohoku J Exp Med. 2016;238:279–86. https://doi.org/10.1620/tjem.238.279.CrossRefPubMed

35.

Krishnappa P, Kong HM, Mohamad IB, Voon K, Somanath SD. CD40 polymorphism in cervical carcinoma in a subset of malaysian population. J Obstet Gynaecol Res. 2017;43:923–8.CrossRefPubMed

36.

Yan ZL, Yang XL, Zhang HP, Yin CM, Zhang S, Li WL, Li HY. Association of polymorphisms in CD40 gene with cervical cancer in chinese Han population in Yunnan province. Chin J Cancer Prev Treat. 2017;24:1331–4.

37.

Chen K, Zhou YX, Li K, et al. A novel three-round multiplex PCR for SNP genotyping with next generation sequencing[J]. Anal Bioanal Chem. 2016;408(16):4371–7. https://doi.org/10.1007/s00216-016-9536-6.CrossRefPubMed

38.

Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics. 2011;27:2987–93. https://doi.org/10.1093/bioinformatics/btr509.CrossRefPubMedPubMedCentral

39.

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559–75. https://doi.org/10.1086/519795.CrossRefPubMedPubMedCentral

40.

Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15:97–8. https://doi.org/10.1038/sj.cr.7290272.CrossRefPubMed

41.

Bahrami A, Hasanzadeh M, ShahidSales S, Yousefi Z, Kadkhodayan S, Farazestanian M, et al. Clinical significance and prognosis value of wnt signaling pathway in Cervical Cancer. J Cell Biochem. 2017;118:3028–33. https://doi.org/10.1002/jcb.25992.CrossRefPubMed

42.

Bergmann S, Pandolfi PP. Giving blood: a new role for CD40 in tumorigenesis. J Exp Med. 2006;203:2409–12.CrossRefPubMedPubMedCentral

43.

Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649–55. https://doi.org/10.1200/JCO.2009.21.8909.CrossRefPubMedPubMedCentral

44.

Chuai Y, Rizzuto I, Zhang X, Li Y, Dai G, Otter SJ, et al. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer. Cochrane Database Syst Rev. 2021;3:CD013348.PubMed

45.

Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992;52:3317–22.PubMed

46.

Tan A, Xia N, Gao F, Mo Z, Cao Y. Angiogenesis-inhibitors for metastatic thyroid cancer. Cochrane Database Syst Rev. 2010;2010:CD007958.PubMedPubMedCentral

47.

Flaxenburg JA, Melter M, Lapchak PH, Briscoe DM, Pal S. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves ras and phosphatidylinositol 3-kinase. J Immunol. 2004;172:7503–9. https://doi.org/10.4049/jimmunol.172.12.7503.CrossRefPubMed

48.

Zirlik A, Bavendiek U, Libby P, MacFarlane L, Gerdes N, Jagielska J, et al. TRAF-1, -2, -3, -5, and – 6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27:1101–7. https://doi.org/10.1161/ATVBAHA.107.140566.CrossRefPubMed

49.

Zhang B, Wu T, Song C, Chen M, Li H, Guo R. Association of CD40–1 C/T polymorphism with cerebral infarction susceptibility and its effect on sCD40L in chinese population. Int Immunopharmacol. 2013;16:461–5. https://doi.org/10.1016/j.intimp.2013.04.028.CrossRefPubMed

50.

Chen P, Sun R, Pu Y, Bai P, Yuan F, Liang Y, et al. Pri-Mir-34b/C and Tp-53 polymorphisms are Associated with the susceptibility of papillary thyroid carcinoma: a case-control study. Med (Baltim). 2015;94:e1536.CrossRef

51.

Yi DH, Wang BG, Zhong XP, Liu H, Liu YF. Pri-miR-34b/c rs4938723 TC heterozygote is associated with increased cancer risks: evidence from published data. Tumour Biol. 2014;35:11967–75.CrossRefPubMed

52.

S E B AA. H S, H P, S H. CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. Journal of immunology (Baltimore, Md.: 1950). 1999;162(7):4140-7.

53.

Angiolo G, Maria Elena G, Carlo G. Tissue biomarkers as prognostic variables of cervical cancer. Crit Rev Oncol Hematol. 2013;86(2):104–29. https://doi.org/10.1016/j.critrevonc.2012.09.003.CrossRef

54.

Lu YF, Mauger DM, Goldstein DB, Urban TJ, Weeks KM, Bradrick SS. IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci Rep. 2015;5:16037.CrossRefPubMedPubMedCentral

Title: Impact of CD40 gene polymorphisms on the risk of cervical squamous cell carcinoma: a case-control study
Authors: Manning Zhu
Xiaoying Li
Yanan Feng
Tianshuang Jia
Songxue Li
Liping Gong
Shuang Dong
Xianchao Kong
Litao Sun
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Human Papillomavirus
Cervical Cancer
Cervical Cancer
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-11367-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer

PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials

Survival of cervical cancer patients at Moi teaching and Referral Hospital, Eldoret in western Kenya

A comprehensive analysis of different types of databases reveals that CDH1 mRNA and E-cadherin protein are not downregulated in most carcinoma tissues and carcinoma cell lines

Two machine learning-based nomogram to predict risk and prognostic factors for liver metastasis from pancreatic neuroendocrine tumors: a multicenter study

Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer